Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Interpace Diagnostics Thyroid Tests Covered In-Network by BCBS of Michigan

Interpace Diagnostics Thyroid Tests Covered In-Network by BCBS of Michigan

Jul 31, 2019
|
staff reporter

NEW YORK – Parsippany, New Jersey-based Interpace Diagnostics announced today that it has signed a contract with Blue Cross Blue Shield of Michigan to cover its ThyGeNext and ThyraMir thyroid cancer detection assays as an in-network service, limiting the insurer's members' out-of-pocket expenses. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Cancer

  1. Paige Secures Additional $15M, Bringing Total Series B Funding to $70M

  2. Amid Interest Generated by Coronavirus Testing, IPO Window Open for Dx Firms in 2020

    Premium

  3. Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer

  4. NCI Researchers Leverage Machine Learning for Accurate, Broader-Scale Cervical Cancer Screening

    Premium

  5. Payor Policy Study Reveals Progress, Challenges in Liquid Biopsy Reimbursement

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.